{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-118166","form_type":"8-K","ticker":"TRAW","cik":"0001130598","company_name":"Traws Pharma, Inc.","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.312122+00:00","generated_at":"2026-06-08T03:12:20.516569+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Onconova Q3 net loss $4.7M; cash $25.2M; narazaciclib dose escalation extended into Q1 2024","bullets":["Net loss Q3 2023: $4.7M ($0.23/sh) vs $5.4M ($0.26/sh) year ago; cash $25.2M sufficient into Q3 2024.","Narazaciclib Phase 1/2 dose escalation extended to at least one more cohort; no significant neutropenia or diarrhea.","Rigosertib registrational trial plan update for RDEB-associated SCC expected in first half of 2024.","Preclinical data for narazaciclib to be presented at SABCS and ASH in December 2023.","Appointed Dr. Victor Moyo as CMO and Meena Arora as VP Medical Affairs in Q3 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-118166","json":"https://secwatch.observer/filing/0001104659-23-118166.json","markdown":"https://secwatch.observer/filing/0001104659-23-118166.md","text":"https://secwatch.observer/filing/0001104659-23-118166.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1130598/000110465923118166/0001104659-23-118166-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1130598/000110465923118166/tm2330724d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T03:12:20.516569+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"76b97a02ce527fa7eba67ce6b35bbee3405c6922","claim":"Traws Pharma, Inc. reported third quarter 2023 results: net income Net loss for the third quarter of 2023 was $4.7 million, or $0.23 per share on 21.0 million weighted average shares outs, EPS $0.23 per share.","evidence_excerpt":"Net loss for the third quarter of 2023 was $4.7 million, or $0.23 per share on 21.0 million weighted average shares outstanding","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465923118166/0001104659-23-118166-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter 2023"},{"label":"Net income","value":"Net loss for the third quarter of 2023 was $4.7 million, or $0.23 per share on 21.0 million weighted average shares outs"},{"label":"EPS","value":"$0.23 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}